Biotech Startups

Holobiome discovers and develops therapies derived from the human gut microbiome, working to translate microbiome science into probiotics and targeted treatments for whole-body health. The company was founded by research scientists from Northeastern University.

9 investors

Hoxton Farms grows cultivated fat, a biomanufactured ingredient for food companies to use in plant-based and alternative meat products. The company operates a production facility in London and partners with global food manufacturers to supply this ingredient.

9 investors

Humane Genomics develops oncolytic viral therapies designed to selectively target and kill cancer cells using engineered RNA viruses, particularly Vesicular Stomatitis Virus. The company leverages a computational platform for viral genome design and engineering to create cancer treatments with improved safety, efficacy, and manufacturing efficiency.

9 investors

Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.

9 investors

Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient. The company focuses on personalized protein therapeutics for patients.

9 investors

Karius is a company that provides microbial cell-free DNA (mcfDNA) metagenomic sequencing services for research and clinical applications. The company runs an Investigator-Initiated Studies grants program to support independent research on diagnostic testing outcomes, health economics, and fundamental science related to its sequencing technology.

9 investors

Mediartx develops novel therapies for patients with fibrotic diseases.

9 investors

Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG). It uses a "search & development" strategy to identify and advance drug programs for specific patient populations.

9 investors

Nicoya provides digital biosensing instruments for biophysical characterization, enabling scientists to study molecular behavior and protein interactions in drug discovery and structural analysis. The company serves research institutions and biotech discovery teams with label-free binding kinetics, thermal shift screening, and hydrogen-deuterium exchange technologies.

9 investors

NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2. It focuses on precision medicine for difficult-to-drug oncology targets, with three compounds advanced into first-in-human clinical testing.

9 investors

Noetik builds AI models to identify cancer patients most likely to respond to treatments and to discover new oncology drug targets. The platform aims to improve clinical trial patient selection and expand the set of viable cancer targets in drug development.

9 investors

OrganOx develops the metra platform, a device that extends organ preservation time for liver transplants by maintaining continuous perfusion with oxygenated blood-based solutions, enabling surgeons to better assess organ viability and make more informed transplant decisions.

9 investors

Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.

9 investors

Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis. Its lead investigational drug, opelconazole, is an inhaled antifungal agent in Phase 3 trials for patients with invasive pulmonary aspergillosis not responding to standard care.

9 investors

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.

9 investors

Rubedo Life Sciences develops therapeutics targeting aging by eliminating senescent cells to extend human healthspan. The company applies artificial intelligence and chemistry to drug discovery in the longevity and regenerative medicine space.

9 investors

Science Exchange operates a marketplace and platform for R&D outsourcing, giving scientists access to external research services and automating the process from sourcing to payment. It serves life sciences companies.

9 investors

Sensible Biotechnologies develops a cell-based mRNA design and manufacturing platform that produces pure, low immunogenicity mRNA therapeutics for drug development. The platform addresses limitations of synthetic mRNA by enabling design-based biology approaches.

9 investors

Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.

9 investors

ShiraTronics is a medical device company developing an implantable device to treat chronic migraine disease. It is a privately held company operating in the medical device and healthcare industry.

9 investors

Shiru uses machine learning to discover and design proteins for sustainable food production. The company applies computational methods to develop plant-based protein ingredients.

9 investors

Spore.Bio develops real-time microbial detection technology for industrial quality control, replacing traditional Petri dish culture methods used in factory settings. It combines photonics, AI, and biology to detect, quantify, and identify living microorganisms without reagents or culturing.

9 investors

Strados Labs builds wearable biosensors and a cloud platform that continuously capture and analyze respiratory data — including cough, spirometry, FeNO, and eCOA endpoints — in patients' daily lives. It combines AI detection with review by credentialed respiratory specialists to produce regulatory-grade, audit-ready evidence for pharma sponsors running decentralized clinical trials.

9 investors

Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline. The company serves patients with motor impairment and cognitive decline using a minimally invasive approach inspired by cardiac interventional procedures.

9 investors